IVIEW completed pre-IND meeting with FDA for the development of IVIEW-1501/1502 for the treatment of Chronic Rhinosinusitis (CRS)

Doylestown, Pennsylvania –IVIEW Therapeutics Inc., an innovative, clinical-stage biopharmaceutical company committed to becoming a leader in topical drug development with specialization focus on ophthalmology, and otolaryngology, completed a successful pre-IND meeting with FDA to develop IVIEW-1501/1502 (Povidone Iodine in combination of Budesonide Nasal Irrigation and Nasal Spray Compositions) for the treatment of Chronic Rhinosinusitis (CRS).

CRS is the result of mixed inflammatory and infectious processes that concurrently affects the noses and para-nasal sinuses. It is a debilitating disease that can lead to significant physical symptoms and substantial functional impairment. The condition is defined by a constellation of symptoms and prolonged clinical course, affecting as many as 30 million US adults per year. Persistence of infection can lead to chronic mucosal inflammation, altered sinonasal ciliary function, and nasal polyp formation. IVIEW-1501/1502 (Povidone Iodine in combination of Budesonide Nasal Irrigation and Nasal Spray Compositions) addresses the underlying infectious pathology from both planktonic and biofilm sources, and can alleviate the concomitant inflammatory response, with a longer therapeutic effect. This tripartite approach to CRS disease addresses all causative pathways and chemically reduces the host immune response that leads to prolonged disease.

The successful pre-IND meeting has granted IVIEW valuable information on preparation of a Phase II IND submission, which the agency agreed on moving into patient efficacy studies directly. FDA has requested IVIEW to perform additional GLP animal toxicology study before entering human efficacy studies. IVIEW has taken vital actions in incorporating FDA feedback to conduct the required GLP toxicology studies and expect to submit phase II IND by the end of 2020.

About IVIEW Therapeutics Inc.
IView Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of ophthalmology therapeutics. IVIEW Therapeutics is headquartered in Pennsylvania Biotechnology Center of Bucks County with its China subsidiary located in Hengqin, Zhuhai city. For additional information on IView, please visit the Company’s website at www.iviewtherapeutics.com.

Pennsylvania Biotechnology Center at Bucks County
3805 Old Easton Road
Doylestown PA 18902 USA
Copyright © 2020 iVIEW Therapeutics, Inc. All rights reserved.